SERIES A-1 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC.Aptevo Therapeutics Inc. • November 9th, 2023 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 4, 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SERIES A-2 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC.Common Stock Purchase Warrant • November 9th, 2023 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [__] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the Stockholder Approval Date (as defined below) (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) December 9, 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), up to [__] shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
CONFIDENTIAL Aptevo Therapeutics Inc. Seattle, WA 98121 Attention: Marvin L. White, Chief Executive Officer Re: Aptevo Therapeutics Inc. – Financial Advisory Agreement Dear Mr. White,Aptevo Therapeutics Inc. • November 9th, 2023 • Pharmaceutical preparations • New York
The purpose of this letter (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), to render Financial Services (as defined below) to the Company.
